Fundraising FoxEquulus Therapeutics
1 known investors
Find your way into Equulus Therapeutics
Sign up to see every warm intro you have to Equulus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Equulus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Equulus Therapeutics is a biotech company developing psychedelic-inspired small-molecule therapeutics for central nervous system and psychiatric disorders, including suicidality in depression, substance use disorder, PTSD, obesity, and seizure disorders. It uses a serotonin releaser technology platform to design compounds intended to retain therapeutic effects while reducing cardiotoxicity, hallucinatory, and abuse-related liabilities.
Founders & leadership
RD
Robert DiscordiaCo-Founder, President & CEO
PH
Peter HendricksCo-Founder & Director, Clinical Psychology
BB
Bruce BloughCo-Founder & Director, Medicinal Chemistry
KM
Kevin MurnaneCo-Founder & Director, Neuropharmacology & Neurotoxicology
DM
Drew MoutonCo-Founder & Chief Business Officer
Investors · 1
Frequently asked questions
- What does Equulus Therapeutics do?
- Equulus Therapeutics is a biotech company developing psychedelic-inspired small-molecule therapeutics for central nervous system and psychiatric disorders, including suicidality in depression, substance use disorder, PTSD, obesity, and seizure disorders. It uses a serotonin releaser technology platform to design compounds intended to retain therapeutic effects while reducing cardiotoxicity, hallucinatory, and abuse-related liabilities.
- Who are Equulus Therapeutics's investors?
- Equulus Therapeutics's investors include Mystic Ventures.